


Form PTO-1449 (Rev. 8-88)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.  C-3169/1/US	Serial No.  09/451,641		
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				Applicant  <b>Gao, D. et al.</b>			
				Filing Date  <b>November 30, 1999</b>	Group No.  <b>1614</b>		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial*	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
S.T.	AA	5,760,068	Talley et al	514	403		
S.T.	AB	5,466,823	Talley et al.	548	377.1		
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
S.T.	BA	0 863 134	Sep 9, 1998	EPO EP	C07C	317/24	x
S.T.	BB	96/37476	Nov 28, 1996	WIPO WO	C07D	231/12	x
<b>OTHER DOCUMENTS</b> (Including author, title, date, pertinent pages, etc.)							
S.T.	CA	Lipsky & Isakson (1997). Outcome of specific COX-2 inhibition in rheumatoid arthritis. Journal of Rheumatology 24 (Supp. 49): 9-14.					
S.T.	CB	Penning et al. (1997). Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). Journal of Medicinal Chemistry 40, 1347-1365.					
S.T.	CC	Simon et al. (1998). Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis & Rheumatism 41, 1591-1602.					
Examiner  S.T.			Date Considered  01/04/01				
*Examiner Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							